IC‐P‐105: Self‐reported versus informant‐based cognitive complaints: Relation of E‐Cog scores to imaging biomarkers and clinical status in ADNI‐2 (original) (raw)

Background: Cerebral microhemorrhages (MH), defined as small, hypointense lesions on T2/T2* weighted images, occur in approximately 23% of Alzheimer's disease (AD) cases. Furthermore, anti-amyloid treatment trials have been associated with the development of MHs . As a response to concerns about the safety of increased MH loads, the Alzheimer's Association Research Roundtable Workgroup recommended that individuals with more than 4 MHs be excluded from clinical trials. There is, however, only one extant in vivo study examining the prevalence of MH in autosomal dominant cases of AD (ADAD). With clinical trials of amyloid modifying agents soon to begin in ADAD populations, there is a pressing need to establish the prevalence of MH in this disease. Methods: Individuals from families with a history of ADAD were recruited at 11 sites worldwide, as part of the DIAN initiative. In total, 96 non-carriers (NC) and 142 carriers (M+) were studied. Longitudinal MH data was available for 25 non-carriers and 59 carriers. A 3T susceptibility-weighted imaging (SWI) sequence was used to quantify the number of MHs in each participant. Following the recommendation of Sperling et al., instances of siderosis were included along with MH counts. Results: Approximately 26% (15/57) of symptomatic (CDR>0) ADAD mutation carriers had at least one MH (Table ). Of the 142 mutation carriers, only 6 had more than four MHs. None of these participants carried the Dutch (Glu693Gln or E693Q) mutation subtype. Within mutation carriers there was clear association with CDR: both the M+/CDR¼0.5 and M+/CDR>0.5 groups had greater MH counts than the M+/CDR¼0 group (p<0.0001).